{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-025606","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.991785+00:00","generated_at":"2026-06-13T02:17:43.019114+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Qualigen sells FastPack diagnostics business for $5.1M; deconsolidates Nanosynex","bullets":["Base sale price $5.8M; net cash received $4.7M at closing plus $450K escrow for indemnification.","FastPack diagnostics business sold to Chembio Diagnostics (subsidiary of Biosynex) in all-cash deal closed July 20, 2023.","Qualigen's ownership in Nanosynex reduced from 52.8% to 49.97% via surrender of preferred B shares; $2.88M notes cancelled; deconsolidation.","Company will advance $1.23M total to Nanosynex in two tranches by March 2024 against promissory notes.","Pro forma shows cash and cash equivalents increase to $7.6M from $4.4M historical; retained equity method investment of $2.94M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-025606","json":"https://secwatch.observer/filing/0001493152-23-025606.json","markdown":"https://secwatch.observer/filing/0001493152-23-025606.md","text":"https://secwatch.observer/filing/0001493152-23-025606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/0001493152-23-025606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:17:43.019114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9064e8ee2f5da52f625c7caf0601b4568c7fd1a0","claim":"AIxCrypto Holdings, Inc. completed a disposition involving Chembio Diagnostics, Inc. for $5.1 million in cash (closed 2023-07-20).","evidence_excerpt":"the consummation of the Transaction, the Subsidiary became a wholly-owned subsidiary of the Buyer. The aggregate net purchase price paid to the Company for the Shares was $5.1 million in cash, based on a base purchase price of $5.8 million, subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by the Subsidiary as","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/0001493152-23-025606-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Chembio Diagnostics, Inc."},{"label":"Consideration","value":"$5.1 million in cash"},{"label":"Closing","value":"2023-07-20"}],"fact_type":"ma_transaction"},{"claim_id":"abb407005f2f7e519320e8867aa684d63509b9c9","claim":"AIxCrypto Holdings, Inc. entered into Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. valued at $5.1 million in cash, based on a base purchase price of $5.8 million (effective 2023-07-20).","evidence_excerpt":"On July 20, 2023, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics, Inc. (the “Buyer”), Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company (the “Subsidiary”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/0001493152-23-025606-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Chembio Diagnostics, Inc. and Biosynex, S.A."},{"label":"Value","value":"$5.1 million in cash, based on a base purchase price of $5.8 million"},{"label":"Effective","value":"2023-07-20"}],"fact_type":"material_agreement"},{"claim_id":"d2498ed7d722f40e441adc6481c46b69b15bb5c0","claim":"AIxCrypto Holdings, Inc. amended Nanosynex Amendment with Nanosynex Ltd. valued at aggregate amount of $1,610,000 (effective 2023-07-20).","evidence_excerpt":"On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with Nanosynex Ltd. (the “Nanosynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of Nanosynex Ltd. (“Nanosynex”), dated May 26, 2022, by and between the Company and Nanosynex (the “Original Nanosynex Agreement”), a majority owned subsidiary of the Company, to, among other things, provide for the further funding of Nanosynex, as contemplated by the Original Nanosynex Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/0001493152-23-025606-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"Nanosynex Ltd."},{"label":"Value","value":"aggregate amount of $1,610,000"},{"label":"Effective","value":"2023-07-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}